“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...
An increasing number of people are dying of colorectal cancer at a young age. The death of actor James Van Der Beek, who was diagnosed with colorectal cancer in 2023, at age 48 is bringing the disease ...
Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.
"Understanding the rates of false-positives and false-negatives in lymph node assessment allows for better-informed surgical decision-making. This contributes to determining the extent of LN ...
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a ...
The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...
Stage 4 colon cancer symptoms like pain and bowel changes can be managed with medicine. Stage 4 colon cancer is not curable, but treatment can help people live longer. Removing a few metastases in the ...
Oct. 22, 2002 — For treatment of metastatic colon cancer, adding oxaliplatin to 5-fluorouracil (5-FU) and leucovorin continues to be superior to 5-FU and leucovorin alone in terms of response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results